Overview

Bioequivalence Study to Compare Dolutegravir 50mg Film-coated Tablets

Status:
COMPLETED

Trial end date:
2024-03-07

Target enrollment:

Participant gender:

Summary

Randomized, two-way, two-period, single oral dose, open-label, crossover, bioequivalence study to compare Dolutegravir 50mg film-coated tablets (50mg Dolutegravir) versus Tivicay 50mg film-coated tablets (50mg Dolutegravir) in healthy subjects under fasting conditions.

Phase:

PHASE1

Details

Lead Sponsor:

Humanis Saglık Anonim Sirketi

Treatments:

dolutegravir